Targeting brain tumors with a specific drug infusion and re-irradiation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of super selective intra-arterial infusion of Cetuximab, combined with hypofractionated re-irradiation, for patients with relapsed or refractory glioblastoma, anaplastic astrocytoma, and anaplastic oligoastrocytoma. The approach aims to directly deliver the drug to the tumor site, potentially enhancing its efficacy while minimizing systemic exposure. The study focuses on patients with confirmed EGFR overexpression, a common characteristic in these aggressive brain tumors, to assess safety and effectiveness. By targeting the tumor more precisely, the trial seeks to improve treatment outcomes for this challenging condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female patients of ≥18 years of age
* Patients with a documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic oligoastrocytoma (AOA)
* Patients with pathology confirmed histologic EGFR overexpression
* Patients must have at least one confirmed and evaluable tumor site.∗

  \*A confirmed tumor site is one in which is biopsy-proven
* Patients must have a Karnofsky performance status ≥60% and an expected survival of ≥ three months.
* No chemotherapy for two weeks prior to treatment under this research protocol and no external beam radiation for eight weeks prior to treatment under this research protocol
* Patients must have adequate hematologic reserve with WBC≥3000/mm3, absolute neutrophils ≥1500/mm3 and platelets ≥100,000/ mm3. Patients who are on Coumadin must have a platelet count of ≥150,000/ mm3
* Pre-enrollment chemistry parameters must show: bilirubin\<1.5X the institutional upper limit of normal (IUNL); AST or ALT\<2.5X IUNL and creatinine\<1.5X IUNL
* Pre-enrollment coagulation parameters (PT and PTT) must be ≤1.5X the IUNL
* Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study
* Patients must be able to understand and give written informed consent. Informed consent must be obtained at the time of patient screening

Exclusion Criteria:

* Women who are pregnant or lactating.
* Women of childbearing potential and fertile men will be informed of the potential unknown risk of conception while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period
* Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring
* Patients with radiological evidence of leptomeningeal disease
* Patients with history of allergic reaction to CTX
* Patients who completed chemo/RT less than 6 months prior to enrollment
* Patients who have not failed standard Stupp protocol

Where it's running

• Lenox Hill Brain Tumor Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: John Boockvar, MD — Northwell Health
• Study coordinator: John Boockvar, MD
• Email: jboockvar@northwell.edu
• Phone: 212-434-3900

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment of newly diagnosed glioblastoma using targeted drug infusion

  This study is testing a new way to deliver a targeted drug directly to the brain tumor in people with newly diagnosed glioblastoma to see if it can improve their treatment outcomes.

  Recruiting Phase 1/2 Northwell Health · New York, New York · NCT02861898

• Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer

  This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06640582

• Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma

  This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.

  Recruiting at 2 sites Phase 3 NaviFUS Corporation · Taipei and 1 other locations · NCT06496971

• Gene therapy combined with radiotherapy for brain tumors

  This study is testing a new gene therapy combined with targeted radiation to see if it can safely help people with recurrent high-grade brain tumors.

  Recruiting Phase 1 Henry Ford Health System · Detroit, Michigan · NCT05686798

• Using omental tissue to treat recurrent glioblastoma

  This study is testing whether using a piece of fat from the abdomen can help improve treatment for patients with recurrent glioblastoma by delivering medication and immune cells more effectively to the tumor site.

  Recruiting Northwell Health · New York, New York · NCT05979064

• Using laser therapy and radiation to treat newly diagnosed gliomas

  This study is testing a new treatment that combines laser therapy and radiation to see if it helps people with newly diagnosed brain tumors called gliomas.

  Recruiting at 5 sites University of Maryland, Baltimore · Baltimore, Maryland and 4 other locations · NCT04699773

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.